JKN 2501
Alternative Names: JKN-2501Latest Information Update: 31 Oct 2025
At a glance
- Originator Joincare Pharmaceutical
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bacterial infections; Intra-abdominal infections; Respiratory tract infections; Urinary tract infections
Most Recent Events
- 22 Aug 2025 Phase-I clinical trials in Bacterial infections (In volunteers) in China (IV) (NCT07207291)
- 22 Aug 2025 Phase-I clinical trials in Intra-abdominal infections (In volunteers) in China (IV) (NCT07207291)
- 22 Aug 2025 Phase-I clinical trials in Respiratory tract infections (In volunteers) in China (IV) (NCT07207291)